| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Innovative Eyewear, Inc. Common Stock$0.77
+0.04 (+6.03%)
Market Cap
6.80 M
EPS
-2.10
P/E Ratio
-0.51 $
Value Trade
81.71 K
SEC Financials
Q3 2025Dilution Risk
Revenue
668.13 K
R&D Expenses
129.98 K
Total Assets
11.18 M
Total Liabilities
925.00 K
Equity
10.25 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
6.70 M
Monthly Burn
612.00 K
Runway
7 mo
Burn Trend
StableSEC Filing
Nov 13, 2025
Overview
Volume
71.36 K
52 Week Range
0.95 - 4.97
% held by Insiders
10.05 %
% held by Institutions
9.03 %
Enterprise Value
322.17 K
Total Shares
6.30 M
Short %
0.59 %
Float Shares
5.69 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LUCY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Innovative Eyewear, Inc. Common Stock (LUCY) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
LUCY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LUCY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LUCY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LUCY Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LUCY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-LUCY
Jun 23, 2026Innovative Eyewear, Inc. Partners with Encore Optical Laboratory to Provide New Lens Technologies for Smart Eyewear
Innovative Eyewear, Inc. has partnered with Encore Optical Laboratory to enhance its smart eyewear offerings. This collaboration introduces advanced lens technologies, including Chemistrie lens clips and Zeiss PhotoFusion X lenses, which provide various functionalities and rapid tint changes. The partnership aims to expand prescription options for Lucyd Armor safety glasses, catering to a broader market.
Read more →-LUCY
Jan 7, 2026Innovative Eyewear, Inc. Announces Record-Breaking 65% Annual Sales Growth in 2025 & Insider Buying Intent MIAMI
Innovative Eyewear, Inc. (LUCY) has announced a record-breaking 65% annual sales growth for 2025, with preliminary sales of approximately $2.7 million. The company attributes this growth to its smart eyewear portfolio and maintains a 44% market share in smart safety glasses on Amazon. Management is optimistic about future prospects, including planned share purchases by executives, which reflects their confidence in the company’s market position and growth strategy. The company expects to secure significant retail placements in 2026 as it continues to expand its distribution channels.
Read more →-LUCY
Jun 23, 2025Innovative Eyewear, Inc. Announces $4.8 Million of Gross Proceeds Raised from Warrant Transactions $2.2 million gross proceeds from warrant inducement transaction $2.6 million gross proceeds from additional warrant exerc
Innovative Eyewear, Inc. (LUCY) announced the successful raising of $4.8 million through warrant transactions, including $2.2 million from a warrant inducement transaction and $2.6 million from additional warrant exercises. The funds are expected to support working capital and general corporate purposes. This financial boost highlights investor confidence in the company's smart eyewear products. The company plans to file a registration statement with the SEC to cover the resale of shares associated with the newly issued warrants.
Read more →-LUCY
Apr 11, 2025E xhibit 99.1 Innovative Eyewear, Inc. Announces Exercise of Warrants for $1.8 Million Gross Proceeds MIAMI
Innovative Eyewear, Inc. has announced that it will exercise certain outstanding warrants, resulting in gross proceeds of $1.8 million. The warrants are being exercised at a reduced price of $2.60 per share, and the transaction is expected to close around April 14, 2025. The funds raised will primarily be used for working capital and general corporate purposes, while new warrants will also be issued during this process. H.C. Wainwright & Co. is serving as the exclusive placement agent for this offering.
Read more →-LUCY
Sep 25, 2024Innovative Eyewear, Inc. Adopts Limited Duration Stockholders Rights Plan MIAMI
Innovative Eyewear, Inc. has announced the adoption of a limited duration stockholders rights plan to protect the company's interests and its investors. This plan allows stockholders to receive rights for each outstanding share, which becomes exercisable if someone acquires 20% or more of the common stock without board approval. The rights plan is designed to prevent hostile takeovers and ensure that stockholders can maximize the value of their investments. It is set to expire on September 25, 2025, unless extended or modified by the board.
Read more →-LUCY
Sep 23, 2024Innovative Eyewear, Inc. Announces Exercise of Warrants for $2.6 Million Gross Proceeds MIAMI
Innovative Eyewear, Inc. announced the immediate exercise of certain warrants that will generate approximately $2.6 million in gross proceeds. The company plans to use the funds for working capital and general corporate purposes. Alongside this exercise, new Series E and Series F warrants will be issued. H.C. Wainwright & Co. is acting as the exclusive placement agent for this transaction, which is subject to customary closing conditions.
Read more →-LUCY
Sep 5, 2024Innovative Eyewear, Inc.
Innovative Eyewear, Inc. announced the immediate exercise of certain outstanding warrants, resulting in the issuance of 126,699 shares of common stock. The exercise is at a reduced price of $5.00 per share, significantly lower than the original price of $21.00. The total gross proceeds from this transaction are expected to be around $633,495. The company will use the funds for working capital and general corporate purposes. Additionally, new unregistered Series A and Series B warrants will also be issued as part of this agreement.
Read more →-LUCY
Jan 5, 2024Eyewear, Inc.
Innovative Eyewear, Inc. (NASDAQ: LUCY) has announced a new license agreement with IngenioSpec LLC, which covers multiple patents related to smart eyewear. This agreement is expected to enhance Innovative Eyewear's product offerings in the competitive smart eyewear marketplace. CEO Gross expressed optimism about the strategic advantage provided by this collaboration, considering the company's existing portfolio of over 60 patents. The development underscores Innovative Eyewear's commitment to innovation in the optical market.
Read more →-LUCY
Jun 22, 2023Innovative Eyewear Announces Pricing of $4.7 Million Public Offering MIAMI
Innovative Eyewear Inc. has announced the pricing of a public offering amounting to $4.7 million, involving 4,500,000 units priced at $1.05 each. Each unit consists of one share of common stock and one warrant for an additional share at the same price. The company plans to use the proceeds primarily for working capital and general corporate purposes. This offering is set to close on June 26, 2023, pending customary closing conditions.
Read more →-LUCY
Dec 28, 2022Innovative Eyewear Inc.
Innovative Eyewear Inc. Nasdaq: LUCY _________________________________ Investor Presentation - Dec. 2022 2022 Innovative Eyewear, Inc. IMPORTANT NOTICE This presentation contains "forward looking statements" within the meaning of Section 27 A of the Securities Act of 1933 as ame
Read more →Competitive Position
How LUCY ranks across every disease it competes inCompetitive Position is a premium feature
See how LUCY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial